Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 730

1.

Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients.

Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, Pedersen RA, Dierkhising RA, Patel R, Razonable RR.

J Heart Lung Transplant. 2007 Oct;26(10):1019-24.

PMID:
17919622
[PubMed - indexed for MEDLINE]
2.

Delayed-onset primary cytomegalovirus disease after liver transplantation.

Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR.

Liver Transpl. 2007 Dec;13(12):1703-9.

PMID:
18044717
[PubMed - indexed for MEDLINE]
Free Article
3.

Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.

Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, Razonable RR.

Clin Infect Dis. 2008 Mar 15;46(6):840-6. doi: 10.1086/528718.

PMID:
18260785
[PubMed - indexed for MEDLINE]
Free Article
4.

Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.

Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK.

Pharmacotherapy. 2004 Oct;24(10):1323-30.

PMID:
15628830
[PubMed - indexed for MEDLINE]
5.

Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.

Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR.

Clin Transplant. 2008 Mar-Apr;22(2):162-70. doi: 10.1111/j.1399-0012.2007.00761.x.

PMID:
18339135
[PubMed - indexed for MEDLINE]
6.

Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.

Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.

Transplant Proc. 2007 Sep;39(7):2228-30.

PMID:
17889146
[PubMed - indexed for MEDLINE]
7.

Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients.

Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP.

Clin Infect Dis. 2007 Aug 15;45(4):439-47. Epub 2007 Jul 10.

PMID:
17638191
[PubMed - indexed for MEDLINE]
Free Article
8.

Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.

Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M; VIPP Study Group.

Transplantation. 2012 Jan 15;93(1):61-8. doi: 10.1097/TP.0b013e318238dab3.

PMID:
22094954
[PubMed - indexed for MEDLINE]
9.

Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.

Weng FL, Patel AM, Wanchoo R, Brahmbhatt Y, Ribeiro K, Uknis ME, Mulgaonkar S, Mathis AS.

Transplantation. 2007 Feb 15;83(3):290-6.

PMID:
17297403
[PubMed - indexed for MEDLINE]
10.

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.

Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.

Transplantation. 1998 Dec 27;66(12):1682-8.

PMID:
9884259
[PubMed - indexed for MEDLINE]
11.

Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients.

Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, Berlakovich G, Kovarik J, Klauser R.

Transplantation. 2000 Oct 27;70(8):1174-80.

PMID:
11063336
[PubMed - indexed for MEDLINE]
12.

Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.

Bonaros NE, Kocher A, Dunkler D, Grimm M, Zuckermann A, Ankersmit J, Ehrlich M, Wolner E, Laufer G.

Transplantation. 2004 Mar 27;77(6):890-7.

PMID:
15077033
[PubMed - indexed for MEDLINE]
13.

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.

Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV.

J Infect Dis. 2001 Dec 1;184(11):1461-4. Epub 2001 Oct 23.

PMID:
11709790
[PubMed - indexed for MEDLINE]
Free Article
14.

Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.

Turgeon N, Fishman JA, Doran M, Basgoz N, Tolkoff-Rubin NE, Cosimi AB, Rubin RH.

Transpl Infect Dis. 2000 Mar;2(1):2-10.

PMID:
11429003
[PubMed - indexed for MEDLINE]
15.

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.

Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group.

Am J Transplant. 2004 Apr;4(4):611-20.

PMID:
15023154
[PubMed - indexed for MEDLINE]
Free Article
16.

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.

Shiley KT, Gasink LB, Barton TD, Pfeiffenberger P, Olthoff KM, Blumberg EA.

Liver Transpl. 2009 Aug;15(8):963-7. doi: 10.1002/lt.21769.

PMID:
19642123
[PubMed - indexed for MEDLINE]
Free Article
17.

Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.

Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP.

Chest. 1999 Nov;116(5):1265-72.

PMID:
10559085
[PubMed - indexed for MEDLINE]
18.

Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.

Potena L, Grigioni F, Magnani G, Lazzarotto T, Musuraca AC, Ortolani P, Coccolo F, Fallani F, Russo A, Branzi A.

J Heart Lung Transplant. 2009 May;28(5):461-7. doi: 10.1016/j.healun.2009.02.009.

PMID:
19416774
[PubMed - indexed for MEDLINE]
19.

Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation.

Kaufman DB, Leventhal JR, Gallon LG, Parker MA, Koffron AJ, Fryer JP, Abecassis MM, Stuart FP.

Transplantation. 2001 Dec 27;72(12):1940-5.

PMID:
11773893
[PubMed - indexed for MEDLINE]
20.

Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?

Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.

Transplant Proc. 2005 Sep;37(7):3182-6.

PMID:
16213344
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk